Intravitreal Bevacizumab Injection for Choroidal Neovascularisation Secondary to Angioid Streaks in Pseudoxanthoma Elasticum Patients

Objective: To evaluate the results of intravitreal bevacizumab (IVB) injections in patients with submacular choroidal neovascularization (CNV) due to angioid streaks (AS) in pseudoxanthoma elasticum (PXE). Design: Case SeriesPopulation: Six eyes of 4 patients with CNV due to AS were enrolled in this study.Methods: Subjects were evaluated with visual acuity measurements, direct fundus examinations, fundus fluorescein angiography (FFA) and optical coherence tomography (OCT).Intravitreal bevacizumab 2.5 mg/0.1 ml treatment was applied to the patients who have choroidal neovascularization due to angioid streaks.Follow up examinations were scheduled monthly and injections were repeated when leakage was observed in FFA and subretinal fluid was observed in OCT after first injections.Results: Mean follow-up time was 7.3 months.During this time enrolled eyes received an average of 3 injections.The mean baseline visual acuity was 0.28 which was improved to 0.43 at the last visit.Mean central retinal thickness was 477.3 at baseline and decreased to 277.5 (range 223-467 μm).No ocular or systemic complications were noted.Conclusion: Short-term results in 4 patients reveals that the use of IVB for the management of CNV in patients with AS is an effective method.The treatment of CNV secondary to AS with intravitreal bevacizumab provides stabilization in OCT and an improvement or stabilization in VA.